Shandong Xinhua Pharmaceutical Company Limited (HKG:0719)
Hong Kong · Delayed Price · Currency is HKD 6.37
-0.02 (-0.31%)
Apr 21, 2026, 4:08 PM HKT
HKG:0719 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,631 | 8,324 | 7,956 | 7,295 | 6,360 |
Other Revenue | 123.7 | 142.44 | 144.78 | 207.82 | 200.54 |
| 8,755 | 8,466 | 8,101 | 7,503 | 6,560 | |
Revenue Growth (YoY) | 3.41% | 4.51% | 7.97% | 14.37% | 9.23% |
Cost of Revenue | 7,162 | 6,481 | 5,779 | 5,515 | 4,824 |
Gross Profit | 1,592 | 1,985 | 2,321 | 1,988 | 1,736 |
Selling, General & Admin | 794.06 | 1,017 | 1,287 | 1,106 | 929.12 |
Research & Development | 381.62 | 413.18 | 419.24 | 345.66 | 341.37 |
Other Operating Expenses | 52.66 | 35.88 | 92.18 | 65.31 | 59.27 |
Operating Expenses | 1,235 | 1,475 | 1,809 | 1,522 | 1,332 |
Operating Income | 357.73 | 510.63 | 512.15 | 465.87 | 403.67 |
Interest Expense | -42.43 | -39.74 | -41.15 | -49.71 | -53.1 |
Interest & Investment Income | 15.45 | 20.96 | 21.88 | 18.83 | 16.79 |
Currency Exchange Gain (Loss) | 2.23 | 19.09 | 15.42 | 10.53 | -4.18 |
Other Non Operating Income (Expenses) | -1.02 | -3.41 | -2.72 | -3.38 | -2.45 |
EBT Excluding Unusual Items | 331.96 | 507.53 | 505.59 | 442.15 | 360.72 |
Gain (Loss) on Sale of Assets | 1.99 | 1.42 | 8.73 | 5.54 | 2.07 |
Asset Writedown | -1.11 | -5.12 | -10.29 | -2.61 | -1.88 |
Other Unusual Items | 26.08 | 29.82 | 28.65 | 26.7 | 60.32 |
Pretax Income | 358.92 | 533.65 | 532.69 | 471.77 | 421.23 |
Income Tax Expense | 52.61 | 46.94 | 26.58 | 45.66 | 59.16 |
Earnings From Continuing Operations | 306.3 | 486.71 | 506.11 | 426.11 | 362.07 |
Minority Interest in Earnings | -16.42 | -16.69 | -9.59 | -15.05 | -13.53 |
Net Income | 289.89 | 470.02 | 496.51 | 411.06 | 348.55 |
Net Income to Common | 289.89 | 470.02 | 496.51 | 411.06 | 348.55 |
Net Income Growth | -38.32% | -5.33% | 20.79% | 17.94% | 7.29% |
Shares Outstanding (Basic) | 690 | 682 | 674 | 661 | 627 |
Shares Outstanding (Diluted) | 692 | 688 | 692 | 671 | 627 |
Shares Change (YoY) | 0.50% | -0.54% | 3.20% | 6.93% | -0.02% |
EPS (Basic) | 0.42 | 0.69 | 0.74 | 0.62 | 0.56 |
EPS (Diluted) | 0.42 | 0.68 | 0.72 | 0.61 | 0.56 |
EPS Growth | -38.23% | -5.56% | 18.03% | 9.75% | 6.89% |
Free Cash Flow | 418.13 | 155.19 | -59.85 | 513.48 | 9.89 |
Free Cash Flow Per Share | 0.60 | 0.23 | -0.09 | 0.77 | 0.02 |
Dividend Per Share | 0.150 | 0.275 | 0.250 | 0.200 | 0.150 |
Dividend Growth | -45.45% | 10.00% | 25.00% | 33.33% | - |
Gross Margin | 18.19% | 23.45% | 28.66% | 26.50% | 26.46% |
Operating Margin | 4.09% | 6.03% | 6.32% | 6.21% | 6.15% |
Profit Margin | 3.31% | 5.55% | 6.13% | 5.48% | 5.31% |
Free Cash Flow Margin | 4.78% | 1.83% | -0.74% | 6.84% | 0.15% |
EBITDA | 943.84 | 1,049 | 1,026 | 952.48 | 840.2 |
EBITDA Margin | 10.78% | 12.40% | 12.67% | 12.70% | 12.81% |
D&A For EBITDA | 586.11 | 538.84 | 514.09 | 486.61 | 436.53 |
EBIT | 357.73 | 510.63 | 512.15 | 465.87 | 403.67 |
EBIT Margin | 4.09% | 6.03% | 6.32% | 6.21% | 6.15% |
Effective Tax Rate | 14.66% | 8.80% | 4.99% | 9.68% | 14.04% |
Revenue as Reported | - | - | - | 7,503 | - |
Advertising Expenses | 4.05 | 7.46 | 8.95 | 8.18 | 11.33 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.